Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

RDUS

Approved

TYMLOS (abaloparatide)

Postmenopausal Osteoporosis

February 25, 2021

On 12/15/20 company noted in Nov added 1,326 new patients

Quarterly Sales

SRPT

PDUFA

CASIMERSEN (SRP-4045)

Duchenne muscular dystrophy

February 25, 2021

FDA grants Priority Review Status and sets regulatory action date for February 25, 2021; FDA has indicated it does not currently plan to hold an advisory committee meeting to discuss the application

Approval

AMRN

Approved

Icosapent Etheyl (generic Vascepa)

Cardiovascular Disease

Feb 25, 2021 (est)

Awaiting response to complaint from Hikma est February 22, 2021

Hikma response

DVAX

Approved

Heplisav-B

Hepatitis B Vaccine

February 25, 2021

US commercial launch in Jan 2018. Approved by EMA in Feb 2021.

Quarterly Sales

AERI

Approved

Rhopressa (Rhokiinsa - EU) (netarsudil)(ROCK - rho kinase inhibitor)

Ophthalmology

Feb 25, 2021

Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021

Quarterly Sales

AMRN

Approved

Vascepa (icosapent ethyl)

Cardiovascular disease

February 25, 2021

Approved in the US in 2012, awaiting approval in the EU. NDA accepted for review in China.

Approval decision

AERI

Approved

Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution)

Ophthalmology, intra-ocular pressure (IOP)

Feb 25, 2021

Approved in US in March 2019 and in EU in Jan 2021; Q4 and Full Year 2020 Financial Results on February 25, 2021

Quarterly Sales

RIGL

Approved

TAVALISSE® (fostamatinib disodium hexahydrate)

Adult Chronic Immune Thrombocytopenia (ITP)

February 26, 2021 (Est)

Quarterly Sales

Quarterly Sales

ICPT

Approved

OCALIVA® (obeticholic acid)

Primary Biliary Cholangitis (PBC)

February 26, 2021 (Est)

Quarterly Sales

Quarterly Sales

SBBP

Approved

KEVEYIS® (dichlorphenamide)

Primary Periodic Paralysis

February 26, 2021 (Est)

Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million

Quarterly Sales

biopharm logo

©2021 by BiopharmIQ